It was only a matter of time before people picked up on this...

It was only a matter of time before people picked up on this incredible cancer drug.

Personally I think Phenoxodiol is quite possibly the next Gleevec but for a whole range of cancers. Gleevec only treats one rare form of cancer and generates $1bn in revenues. Ovarian cancer is over 10 times as common as that form of leukemia but Phenoxodiol is targeting a whole range of others including skin cancer.

Yale university is presenting at ASCO starting next week. That conference is attended by over 20000 people including many journo's, doctors, patients etc etc. Novogen will no longer be an "unknown" stock.

Considering the market cap of NVGN is $0.28bn and Genentech is $28.6bn the upside is significant.

Cheers,
Munch.